Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study with Spevatamig (PT886) Followed by a Multi-cohorT Study in Patients with Advanced GastrIc, Gastroesophageal JuNction (GEJ), or Pancreatic Ductal AdEnocarcinomas of Spevatamig (PT886), in Combination with Either ChemotherApy, And/or the ChecKpoint Inhibitor Pembrolizumab. the TWINPEAK Study

Next Previous
Search
Trial Profile

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study with Spevatamig (PT886) Followed by a Multi-cohorT Study in Patients with Advanced GastrIc, Gastroesophageal JuNction (GEJ), or Pancreatic Ductal AdEnocarcinomas of Spevatamig (PT886), in Combination with Either ChemotherApy, And/or the ChecKpoint Inhibitor Pembrolizumab. the TWINPEAK Study

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; PT 886 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Adverse reactions; First in man
  • Acronyms TWINPEAK
  • Sponsors Phanes Therapeutics

    • Most Recent Events

    • 15 Nov 2024 Planned number of patients changed from 114 to 135.
    • 15 Nov 2024 Planned End Date changed from 1 Apr 2026 to 1 Apr 2028.
    • 15 Nov 2024 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top